Literature DB >> 21783418

Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?

Tetsuya Mitsudomi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21783418     DOI： 10.1016/S1470-2045(11)70194-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

Review 1.  From drug discovery to biomarker-driven clinical trials in lymphoma.

Authors:  Anas Younes; Donald A Berry
Journal:  Nat Rev Clin Oncol       Date:  2012-09-11       Impact factor: 66.675

2.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

3.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

4.  Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Authors:  Amit Jain; Cindy Lim; Eugene MingJin Gan; David Zhihao Ng; Quan Sing Ng; Mei Kim Ang; Angela Takano; Kian Sing Chan; Wu Meng Tan; Ravindran Kanesvaran; Chee Keong Toh; Chian Min Loo; Anne Ann Ling Hsu; Anantham Devanand; Chong Hee Lim; Heng Nung Koong; Tina Koh; Kam Weng Fong; Swee Peng Yap; Su Woon Kim; Balram Chowbay; Lynette Oon; Kiat Hon Lim; Wan Teck Lim; Eng Huat Tan; Daniel Shao Weng Tan
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

5.  The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Jing Liu; Xuemei Li; Yinghong Shao; Xiyun Guo; Jinggui He
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.